{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:36:29Z","timestamp":1792496189889,"version":"4.5.0"},"reference-count":71,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T00:00:00Z","timestamp":1473638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2016,11,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent years, but trends vary by subtype. Precursor lymphoid neoplasm incidence rates increased from 2001 to 2012, particularly for B\u2010cell neoplasms. Among the mature lymphoid neoplasms, the fastest increase was for plasma cell neoplasms. Rates also increased for mantle cell lymphoma (males), marginal zone lymphoma, hairy cell leukemia, and mycosis fungoides. Like incidence, survival for both mature T\u2010cell lymphomas and mature B\u2010cell lymphomas varied by subtype and by race. Patients with peripheral T\u2010cell lymphomas had among the worst 5\u2010year relative survival (36%\u201056%, depending on race\/sex), while those with mycosis fungoides had among the best survival (79%\u201092%). For B\u2010cell lymphomas, 5\u2010year survival ranged from 83% to 91% for patients with marginal zone lymphoma and from 78% to 92% for those with hairy cell leukemia; but the rates were as low as 47% to 63% for patients with Burkitt lymphoma and 44% to 48% for those with plasma cell neoplasms. In general, black men had the lowest survival across lymphoid malignancy subtypes. These contemporary incidence and survival statistics are useful for developing management strategies for these cancers and can offer clues regarding their etiology.\n                    <jats:bold>CA Cancer J Clin 2016;66:443\u2013459. \u00a9 2016 American Cancer Society<\/jats:bold>\n                    .\n                  <\/jats:p>","DOI":"10.3322\/caac.21357","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T08:56:48Z","timestamp":1473670608000},"page":"443-459","source":"Crossref","is-referenced-by-count":874,"title":["2016 US lymphoid malignancy statistics by World Health Organization subtypes"],"prefix":"10.3322","volume":"66","author":[{"given":"Lauren R.","family":"Teras","sequence":"first","affiliation":[{"name":"Strategic Director, Hematologic Cancer Research, Epidemiology Research Program American Cancer Society Atlanta GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol E.","family":"DeSantis","sequence":"additional","affiliation":[{"name":"Director, Breast and Gynecological Cancer Surveillance, Surveillance and Health Services Research American Cancer Society Atlanta GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"Professor and Chair, Department of Health Sciences Research Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Morton","sequence":"additional","affiliation":[{"name":"Senior Investigator, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics National Cancer Institute Rockville MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmedin","family":"Jemal","sequence":"additional","affiliation":[{"name":"Vice President, Surveillance and Health Services Research American Cancer Society Atlanta GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Director, Lymphoma Program, Department of Hematology and Oncology\/Winship Cancer Institute Emory University Atlanta GA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.086"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289561"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu013"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.12.001"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10403"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24934"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.15.1240"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0281"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.635540"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0040"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24086"},{"key":"e_1_2_6_15_1","volume-title":"SEER*Stat Database, North American Association of Central Cancer Registries (NAACCR) Incidence\u2010Cancer in North America (CiNA) Analytic File, 2001\u20132012","author":"Surveillance, Epidemiology, and End Results (SEER) Program"},{"key":"e_1_2_6_16_1","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_17_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program (seer.cancer.gov) SEER*Stat Database: Incidence \u2010 SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases Nov 2015 Sub (1973\u20100000 varying) \u2010 Linked To County Attributes \u2010 Total U.S. 1969\u20100000 Counties National Cancer Institute DCCPS Surveillance Research Program Surveillance Systems Branch released April 2016 based on the November 2015 submission."},{"key":"e_1_2_6_18_1","volume-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S","year":"2008"},{"key":"e_1_2_6_19_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Steven H","year":"2008"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_6_21_1","volume-title":"International Classification of Diseases for Oncology","author":"Fritz A","year":"2000"},{"key":"e_1_2_6_22_1","volume-title":"SEER*Stat Software, version 8.2.1","author":"Surveillance Research Program, National Cancer Institute","year":"2015"},{"key":"e_1_2_6_23_1","volume-title":"Joinpoint Regression Program, version 4.2.0.2","author":"National Cancer Institute","year":"2015"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.20.1537"},{"key":"e_1_2_6_25_1","volume-title":"SEER*Stat Database: Incidence\u2010SEER 18 Regs Research Data with Delay\u2010Adjustment, Malignant Only, Nov. 2014 Submission (2000\u20102012) <Katrina\/Rita Population Adjustment>\u2010Linked To County Attributes\u2010Total US, 1969\u20132013 Counties","author":"Surveillance, Epidemiology, and End Results (SEER) Program","year":"2015"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27405"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21219"},{"key":"e_1_2_6_29_1","volume-title":"Epstein\u2010Barr Virus. A Review of Human Carcinogens. Part B: Biological Agents","author":"International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2009"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001623801"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-008-1026-3"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.0151"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu009"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2012.1900"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090720"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.12.020"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv279"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-537498"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10933"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.53.4.245"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu001"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12935"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22718"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3105"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu010"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5827"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.09.004"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu006"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu011"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu008"},{"key":"e_1_2_6_51_1","first-page":"3605","article-title":"Epidemiology of hairy cell leukemia in Los Angeles County","volume":"50","author":"Bernstein L","year":"1990","journal-title":"Cancer Res."},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu004"},{"key":"e_1_2_6_53_1","volume-title":"HIV Surveillance Report, 2014","author":"Centers for Disease Control and Prevention (CDC)","year":"2015"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22047"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.99107s5681"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.39"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022268103136"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010401)91:7<1402::AID-CNCR1145>3.0.CO;2-6"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-355"},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-33"},{"key":"e_1_2_6_61_1","volume-title":"SEER Cancer Statistics Review, 1975\u20132012, based on Nov 2014 SEER data submission","author":"Howlader N","year":"2015"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.025"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12935"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28690"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6444a2"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgu012"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-012-0001-3"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwu016"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24236"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28233"},{"key":"e_1_2_6_72_1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1996.14.3.974","article-title":"Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229","volume":"14","author":"Modiano MR","year":"1996","journal-title":"J Clin Oncol."}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.21357","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:06:58Z","timestamp":1762362418000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,12]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11,12]]}},"alternative-id":["10.3322\/caac.21357"],"URL":"https:\/\/doi.org\/10.3322\/caac.21357","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726732615.793544941","asserted-by":"object"}]},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"value":"0007-9235","type":"print"},{"value":"1542-4863","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,12]]}}}